Cargando…

Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro

INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyyak, Solomiya, Blatt, Sebastian, Schiegnitz, Eik, Heimes, Diana, Staedt, Henning, Thiem, Daniel G. E., Sagheb, Keyvan, Al-Nawas, Bilal, Kämmerer, Peer W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925396/
https://www.ncbi.nlm.nih.gov/pubmed/33681155
http://dx.doi.org/10.3389/fbioe.2021.599224
_version_ 1783659261922902016
author Kyyak, Solomiya
Blatt, Sebastian
Schiegnitz, Eik
Heimes, Diana
Staedt, Henning
Thiem, Daniel G. E.
Sagheb, Keyvan
Al-Nawas, Bilal
Kämmerer, Peer W.
author_facet Kyyak, Solomiya
Blatt, Sebastian
Schiegnitz, Eik
Heimes, Diana
Staedt, Henning
Thiem, Daniel G. E.
Sagheb, Keyvan
Al-Nawas, Bilal
Kämmerer, Peer W.
author_sort Kyyak, Solomiya
collection PubMed
description INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP-2), and osteonectin (OCN). MATERIALS AND METHODS: Cerabone(®) (CB), Bio-Oss(®) (BO), Creos Xenogain(®) (CX) and MinerOss(®) X (MO) ± i-PRF were incubated with HOB. At day 3, 7, and 10, cell viability and metabolic activity as well as expression of ALP, OCN, and BMP-2, was examined. RESULTS: For non-i-PRF groups, the highest values concerning viability were seen for CB at all time points. Pre-treatment with i-PRF increased viability in all groups with the highest values for CB-i-PRF after 3 and 7 and for CX-i-PRF after 10 days. For metabolic activity, the highest rate among non-i-PRF groups was seen for MO at day 3 and for CB at day 7 and 10. Here, i-PRF groups showed higher values than non-i-PRF groups (highest values: CB + i-PRF) at all time points. There was no difference in ALP-expression between groups. For OCN expression in non-i-PRF groups, CB showed the highest values after day 3, CX after day 7 and 10. Among i-PRF-groups, the highest values were seen for CX + i-PRF. At day 3, the highest BMP-2 expression was observed for CX. Here, for i-PRF groups, the highest increase was seen for CX + i-PRF at day 3. At day 7 and 10, there was no significant difference among groups. CONCLUSION: XBSM sintered under high temperature showed increased HOB viability and metabolic activity through the whole period when compared to XBSM manufactured at lower temperatures. Overall, the combination of XBSM with i-PRF improved all cellular parameters, ALP and BMP-2 expression at earlier stages as well as OCN expression at later stages.
format Online
Article
Text
id pubmed-7925396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79253962021-03-04 Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro Kyyak, Solomiya Blatt, Sebastian Schiegnitz, Eik Heimes, Diana Staedt, Henning Thiem, Daniel G. E. Sagheb, Keyvan Al-Nawas, Bilal Kämmerer, Peer W. Front Bioeng Biotechnol Bioengineering and Biotechnology INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP-2), and osteonectin (OCN). MATERIALS AND METHODS: Cerabone(®) (CB), Bio-Oss(®) (BO), Creos Xenogain(®) (CX) and MinerOss(®) X (MO) ± i-PRF were incubated with HOB. At day 3, 7, and 10, cell viability and metabolic activity as well as expression of ALP, OCN, and BMP-2, was examined. RESULTS: For non-i-PRF groups, the highest values concerning viability were seen for CB at all time points. Pre-treatment with i-PRF increased viability in all groups with the highest values for CB-i-PRF after 3 and 7 and for CX-i-PRF after 10 days. For metabolic activity, the highest rate among non-i-PRF groups was seen for MO at day 3 and for CB at day 7 and 10. Here, i-PRF groups showed higher values than non-i-PRF groups (highest values: CB + i-PRF) at all time points. There was no difference in ALP-expression between groups. For OCN expression in non-i-PRF groups, CB showed the highest values after day 3, CX after day 7 and 10. Among i-PRF-groups, the highest values were seen for CX + i-PRF. At day 3, the highest BMP-2 expression was observed for CX. Here, for i-PRF groups, the highest increase was seen for CX + i-PRF at day 3. At day 7 and 10, there was no significant difference among groups. CONCLUSION: XBSM sintered under high temperature showed increased HOB viability and metabolic activity through the whole period when compared to XBSM manufactured at lower temperatures. Overall, the combination of XBSM with i-PRF improved all cellular parameters, ALP and BMP-2 expression at earlier stages as well as OCN expression at later stages. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925396/ /pubmed/33681155 http://dx.doi.org/10.3389/fbioe.2021.599224 Text en Copyright © 2021 Kyyak, Blatt, Schiegnitz, Heimes, Staedt, Thiem, Sagheb, Al-Nawas and Kämmerer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Kyyak, Solomiya
Blatt, Sebastian
Schiegnitz, Eik
Heimes, Diana
Staedt, Henning
Thiem, Daniel G. E.
Sagheb, Keyvan
Al-Nawas, Bilal
Kämmerer, Peer W.
Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title_full Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title_fullStr Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title_full_unstemmed Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title_short Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
title_sort activation of human osteoblasts via different bovine bone substitute materials with and without injectable platelet rich fibrin in vitro
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925396/
https://www.ncbi.nlm.nih.gov/pubmed/33681155
http://dx.doi.org/10.3389/fbioe.2021.599224
work_keys_str_mv AT kyyaksolomiya activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT blattsebastian activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT schiegnitzeik activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT heimesdiana activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT staedthenning activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT thiemdanielge activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT saghebkeyvan activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT alnawasbilal activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro
AT kammererpeerw activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro